Compare Alliant Energy Corporation (LNT) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Tango Therapeutics Inc. — how do they compare? Alliant Energy Corporation trades at $67.51 (market cap $17.36B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Alliant Energy Corporation is far larger — about 4.6× Tango Therapeutics Inc.'s market cap, and Alliant Energy Corporation pays a 3.2% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alliant Energy Corporation for 65 Days and Tango Therapeutics Inc. for 0 Days on average.
| LNT | TNGX | |
|---|---|---|
Market Cap | $17.36B | $3.75B |
Volume | 1,948,386 | 9,619,106 |
Sector | Utilities | Health |
52-Week High | $78.03 | $32.90 |
52-Week Low | $63.21 | $7.50 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $29.46B | $2.77B |
Dividend Yield | 3.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LNT trades at $67.51, up 1.58% with a bullish technical signal despite mixed momentum indicators. The company shows solid fundamentals with Q2 2026 earnings beating expectations at $0.65 per share and maintaining 18.45% net margins. Recent news highlights institutional accumulation and a $13.4 billion capital investment plan through 2029 supporting long-term growth. Analyst consensus remains positive with a $75.17 price target and no sell ratings.
LNT presents a favorable risk-reward profile with strong utility operations, consistent dividend growth, and data center demand driving revenue. Key risks include rising debt levels (48.48% debt-to-asset ratio) and interest rate sensitivity. The stock offers defensive value with upside potential to analyst targets, though investors should monitor execution of the large capex plan and regulatory developments.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
